Funder: Patient-Centered Outcomes Research Institute
Due Dates (Anticipated): May 2026 (Letter of Intent) | September 2026 (Full application)
Funding Amounts: Up to $22 million direct costs total per award (feasibility phase: $2M, full-scale phase: $20M); max duration 6.5 years (1.5 years feasibility + 5 years full-scale)
Summary: Supports large-scale, patient-centered comparative effectiveness randomized trials with a required feasibility phase and strong stakeholder engagement.
Key Information: Forecasted dates—confirm on program page before applying.